With respect to the following questions, please provide answers for any decisions made since 1 January 2016.
A
Has the Department or its committees recommended prescribing a particular brand or brands of seven day buprenorphine transdermal patches? If so, what brand or brands were recommended to be prescribed?
B
If the Department or its committees recommends prescribing more than one brand of 7 day buprenorphine transdermal patches what, if any, guidance is there on which brand(s) should be prescribed?
C
For each brand of seven day buprenorphine transdermal patches recommended, on what date was the decision made to recommend that brand?
No recommendations have been given.
B and C
Not applicable as no recommendations were given.
